home / stock / cmxhf / cmxhf quote
Last: | $192.75 |
---|---|
Change Percent: | 2.22% |
Open: | $193.6 |
Close: | $192.75 |
High: | $193.6 |
Low: | $192.75 |
Volume: | 358 |
Last Trade Date Time: | 07/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$192.75 | $193.6 | $192.75 | $193.6 | $192.75 | 358 | 07-25-2024 |
$198 | $201.88 | $198 | $201.88 | $198 | 140 | 07-24-2024 |
$202.38 | $206 | $202.38 | $206.25 | $196.86 | 1,222 | 07-23-2024 |
$199.001 | $199.04 | $199.001 | $199.04 | $199 | 4,900 | 07-22-2024 |
$197.59 | $197.55 | $197.59 | $197.59 | $197.55 | 150 | 07-19-2024 |
$198.6 | $198.6 | $198.6 | $198.6 | $198.6 | 2 | 07-18-2024 |
$203.04 | $203.04 | $203.04 | $203.04 | $203 | 560 | 07-16-2024 |
$205.5 | $204.04 | $205.5 | $205.5 | $204.04 | 525 | 07-15-2024 |
$204.225 | $198.06 | $204.225 | $204.225 | $197.09 | 1,216 | 07-11-2024 |
$196.04 | $206.65 | $196.04 | $206.65 | $196.04 | 223 | 07-10-2024 |
$197.5 | $194.34 | $197.5 | $200.5 | $194.34 | 450 | 07-09-2024 |
$194.79 | $192.5 | $194.79 | $199.375 | $192.5 | 813 | 07-08-2024 |
$200 | $200 | $200 | $200 | $200 | 666 | 07-05-2024 |
$191 | $191 | $191 | $191 | $191 | 27 | 07-02-2024 |
$192 | $193.8 | $192 | $193.8 | $191 | 675 | 07-01-2024 |
$189.8 | $189.8 | $189.8 | $189.84 | $189.8 | 1,035 | 06-28-2024 |
$189.84 | $189.8 | $189.84 | $189.84 | $189.8 | 1,787 | 06-27-2024 |
$191.79 | $0 | $191.79 | $0 | $0 | 5,000 | 06-26-2024 |
$191.79 | $191.79 | $191.79 | $191.79 | $191.79 | 100 | 06-25-2024 |
$191 | $191.75 | $191 | $194.625 | $190.75 | 4,257 | 06-24-2024 |
News, Short Squeeze, Breakout and More Instantly...
Csl Ltd Company Name:
CMXHF Stock Symbol:
OTCMKTS Market:
New York, United States (ABN Newswire) - OTC Markets Group Inc. (OTCMKTS:OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced CSL Limited (ASX:CSL) (OTCMKTS:CSLLY), a leading global biotechnology company with a dynamic portfolio of lifesaving medicine...
HATTERSHEIM AM MAIN, Germany , Jan. 24, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the Danish Medicines Council has published its final decision, approving human Alpha 1 Antitrypsin (AAT) therapy and Respreeza® as standard treatment for ...